Ireland is home to Recordati’s external supply operations and global in-licensing teams, alongside the API facility for one of the company’s most prolific products; Director Michael Kilkelly discusses the advantages of running such operations in Ireland, beyond the many financial incentives.
In your opinion, why is Ireland such an attractive destination for multinational pharmaceutical companies?
The HPRA is very strict relative to other regulators, meaning if you get a license granted by them it is good enough for the FDA in the US and most other regulatory bodies worldwide
